Breast cancer is the most common malignancy diagnosed in women worldwide, and so the development of new drugs is an important priority. To better understand the evolution of new drug approvals for breast cancer, we analysed approvals of oncology drugs by the US Food and Drug Administration (FDA) during the 70-year period from 1949 (the year of the first oncology drug approval) to 2018 (see Supplementary Box 1 for details).
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Acknowledgements
The authors thank A. Mollet at the European Center for Pharmaceutical Medicine, University of Basel, Switzerland, for her support.
Competing Interests
C.P.L. is employed by HBM Partners, which invests in emerging biotech companies.
